Follow The Filings

EOLS Evolus Inc.

Health Care, filed as EVOLUS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.4%
  • $1.1M

Who owns this now

Largest portfolio weights among holders, up to 0.4% (Michael Krensavage, Krensavage Asset Management). Not free-float ownership.

  1. Michael Krensavage 0.42%

Who owns EOLS

Sorted by value, long equity only, as of 2026 Q2.

History
Michael Krensavage, Krensavage Asset Management 0.42% Hold 157,985 $1.1M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by EOLS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All EOLS insider trades
  • None no insider bought on the open market
  • $950K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. David Moatazedi See Remarks
    Sale
    $950K 105,108 shares at $9.04 17% of stake
    Traded Sep 2 Filed Sep 4
    ↗

Also filed in the last 12 months, not counted as buying or selling: 8 stock grants, 6 sales to cover taxes, and 2 option exercises.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
8-K 1.01,2.02,2.03,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $202.08M $266.27M $297.18M
Gross profit * $140.53M $182.3M $197.11M
Gross margin * 69.5% 68.5% 66.3%
Net income -$61.68M -$50.42M -$51.64M
Net margin * -30.5% -18.9% -17.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $112.42M $151.34M $142.92M
Total non-current assets * $76.58M $81.23M $82.95M
Total assets $189M $232.57M $225.87M
Total current liabilities $48.29M $62.96M $75.3M
Total non-current liabilities * $161.4M $164.09M $173.67M
Total equity -$20.69M $5.52M -$23.11M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$34.01M -$18M -$42.26M
Cash from investing -$1.63M -$4.82M -$8.45M
Cash from financing $44.64M $47.41M $17.34M
Net change in cash $8.92M $24.11M -$33.13M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.